{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:18:04Z","timestamp":1788171484064,"version":"build-2803163510"},"reference-count":27,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of elinzanetant for the management of vasomotor symptoms (VMS) associated with menopause.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>Literature was identified using PubMed (1966 to January 2026), EMBASE (1973 to January 2026), and clinicaltrials.gov. Search terms included elinzanetant, VMS, and menopause, limiting trials to those published in English.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Articles selected for inclusion included trials evaluating elinzanetant for the treatment of VMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>\n                      Elinzanetant was evaluated for reduction in frequency and severity of moderate-to-severe VMS associated with menopause in 3 phase 3 trials (OASIS 1, 2, and 3) and 1 phase 3 trial in patients receiving endocrine therapy for breast cancer (OASIS 4). All studies showed significant improvements in symptom frequency at week 12 compared to placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). Improvement in sleep disturbances and quality of life was also significant in OASIS 1, 2, and 4. Elinzanetant was well-tolerated, with headache, fatigue, dizziness, somnolence, abdominal pain, and rash reported as the most frequent drug-associated adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Elinzanetant is the first dual neurokinin-1 and neurokinin-3 receptor antagonist approved for moderate-to-severe VMS associated with menopause. Elinzanetant offers a nonhormonal treatment option with favorable tolerability, representing a promising alternative for patients who cannot or prefer not to use hormonal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The U.S. Food and Drug Administration approval of elinzanetant provides an additional nonhormonal option for managing moderate-to-severe VMS of menopause in patients for whom hormonal therapy is contraindicated or undesired.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261426643","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:38:41Z","timestamp":1774262321000},"page":"1002-1011","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Elinzanetant: A Novel Approach to Management of Vasomotor Menopausal Symptoms"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8222-1889","authenticated-orcid":false,"given":"Jordan M.","family":"Rowe","sequence":"first","affiliation":[{"name":"Division of Pharmacy Practice and Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Coffman","sequence":"additional","affiliation":[{"name":"University of Missouri-Kansas City School of Pharmacy, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-5164","authenticated-orcid":false,"given":"Kylie N.","family":"Barnes","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S365808"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000441353.20693.78"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002028"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.8063"},{"key":"e_1_3_2_6_2","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms\u2014recommendations for clinical evaluation. Accessed January 13 2026. https:\/\/www.fda.gov\/media\/71359\/download"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5122(96)82006-8"},{"key":"e_1_3_2_8_2","unstructured":"HealthMeasures. PROMIS\u00ae. Accessed January 13 2026. https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91a.23067"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002200"},{"key":"e_1_3_2_11_2","unstructured":"Veozah (Fezolinetant) [package insert]. Astellas Pharma US Inc; 2024."},{"key":"e_1_3_2_12_2","unstructured":"Lynkuet (Elinzanetant) [package insert]. Bayer Healthcare Pharmaceuticals Inc; 2024."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_3_2_14_2","unstructured":"U.S. Food and Drug Administration. HHS advances women\u2019s health removes misleading FDA warnings on hormone replacement therapy. Accessed January 13 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy"},{"key":"e_1_3_2_15_2","unstructured":"U.S. Food and Drug Administration. NDA219469. Accessed January 13 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2025\/219469Orig1s000ltr.pdf"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113480990"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.3208"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.14618"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.4421"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415566"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415566"},{"key":"e_1_3_2_22_2","unstructured":"Lexi-Drugs. Elinzanetant. Uptodate Inc; 2026. Accessed January 27 2026. http:\/\/online.lexi.com"},{"key":"e_1_3_2_23_2","unstructured":"Lexi-Drugs. Elinzanetant. Uptodate Inc; 2026. Accessed January 27 2026. http:\/\/online.lexi.com"},{"key":"e_1_3_2_24_2","unstructured":"GoodRx. Brisdelle 2026 prices coupons & savings tips. Accessed January 13 2026. https:\/\/www.goodrx.com\/brisdelle"},{"key":"e_1_3_2_25_2","unstructured":"George C. HRT cost: hormone replacement therapy pricing explained. GoodRx. Accessed January 26 2026. https:\/\/www.reuters.com\/sustainability\/boards-policy-regulation\/us-fda-approves-bayers-menopause-relief-drug-2025-10-24\/"},{"key":"e_1_3_2_26_2","unstructured":"Lexi-Drugs. Estradiol (Systemic). Uptodate Inc; 2026. Accessed January 27 2026. http:\/\/online.lexi.com"},{"key":"e_1_3_2_27_2","unstructured":"Reuters. US FDA approves Bayer\u2019s menopause relief drug. Accessed January 13 2026. https:\/\/www.reuters.com\/sustainability\/boards-policy-regulation\/us-fda-approves-bayers-menopause-relief-drug-2025-10-24\/"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005812"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261426643","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261426643","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261426643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:53:08Z","timestamp":1788169988000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261426643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10600280261426643"],"URL":"https:\/\/doi.org\/10.1177\/10600280261426643","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}